Beijing Wantai Biological Pharmacy Enterprise Balance Sheet Health
Financial Health criteria checks 5/6
Beijing Wantai Biological Pharmacy Enterprise has a total shareholder equity of CN¥12.6B and total debt of CN¥267.0M, which brings its debt-to-equity ratio to 2.1%. Its total assets and total liabilities are CN¥14.7B and CN¥2.1B respectively.
Key information
2.1%
Debt to equity ratio
CN¥267.03m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥5.50b |
| Equity | CN¥12.61b |
| Total liabilities | CN¥2.13b |
| Total assets | CN¥14.74b |
Recent financial health updates
Recent updates
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year
Jul 26
These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well
Jul 22Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings
Apr 04Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade
Apr 02Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%
Feb 28Financial Position Analysis
Short Term Liabilities: 603392's short term assets (CN¥9.0B) exceed its short term liabilities (CN¥1.9B).
Long Term Liabilities: 603392's short term assets (CN¥9.0B) exceed its long term liabilities (CN¥180.9M).
Debt to Equity History and Analysis
Debt Level: 603392 has more cash than its total debt.
Reducing Debt: 603392 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: 603392's debt is well covered by operating cash flow (316.3%).
Interest Coverage: Insufficient data to determine if 603392's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 07:52 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Zhizhong Jing | China Merchants Securities Co. Ltd. |
| Wei Sun | China Merchants Securities Co. Ltd. |